Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Two further clinical trials are planned to confirm a vaginal gel that has shown potential in reducing the risk of HIV. The results of the first trial of the gel, which were announced in July at the XVIII International AIDS Conference must be confirmed before the product can be made available for general use.
The tenofovir-based gel was found to be 39% effective to reduce a woman's risk of becoming infected with HIV during sex in a study completed by the Centre for the AIDS Programme of Research in South Africa, a UNAIDS Collaborating Centre on HIV prevention research.
The CAPRISA study was conducted in South Africa with women aged 18 to 40 years who used the gel once during the 12 hours before sex and once during the 12 hours after sex.
Experts at a meeting convened last week by the Joint United Nations Programme on HIV/AIDS and the World Health Organization in Johannesburg, South Africa, proposed that further trials should determine whether different populations of women will have the same level of protection as seen in the CAPRISA trial.
One study, which will take place primarily in South Africa, will establish if the CAPRISA results can be repeated in a variety of settings with a population that includes younger women. It will also evaluate whether the gel can be used safely by sexually active 16- and 17-year-olds in settings where HIV incidence is high.
The other study, which will be conducted in other African countries, will examine if a different dosing schedule is safe and effective. It will test if a single application of the gel before sex, or failing that immediately after, is equally effective and safe as the original two dose regimen. The single dose schedule would be less expensive and easier for women to use.
In addition, an ongoing trial being conducted by the Microbicides Trial Network, studying the same gel but used daily, will generate additional data on safety and product use.
Research in the communities where the CAPRISA trial was carried out will also examine how to best promote, distribute, and monitor gel use through existing family planning facilities. This would allow former trial participants and others in their communities to have early access to the new gel, but within the context of programmatic research.
While participants agreed on research priorities, concerns were expressed over the limited funding committed thus far to carry forward the next phase of research, which is estimated to cost US$ 100 million. Only US$ 58 million is available.
Nearly 20 years of research have gone into microbicides. If confirmed, the tenofovir gel would empower women by adding significantly to the options they have to protect themselves from HIV without requiring the cooperation of their male partner. About half the people living with HIV in the world are women. In sub-Saharan Africa more women are infected than men. HIV is a major cause of maternal mortality.
"This promising tenofovir gel is a woman-initiated and controlled HIV prevention tool that could now be within reach," said Dr. Catherine Hankins, Chief Scientific Adviser to UNAIDS. "Funders, advocates, and scientists can work together to close the funding gap rapidly, gather the evidence, and ensure that no time is lost in getting a safe and effective microbicide to women."
Convened at the invitation of the South African government, the meeting brought together members of government agencies from South Africa and other countries, microbicide research teams and product developers, women's health and HIV prevention advocates, people living with HIV, clinical and social science researchers, statisticians, civil society representatives, public health experts, ethicists, and representatives from national drug regulatory authorities.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Before AIDS, gay artist Rex drew hot men on the prowl — then he disappeared
April 11 2024 3:15 PM
Diets that mimic fasting reverse aging: study
March 07 2024 5:28 PM
PrEP without a prescription now a reality in California
February 06 2024 8:37 PM
Injectable HIV treatment, prevention: Everything you need to know
March 26 2024 3:28 PM
8 dating tips for gay men from a gay therapist
March 21 2024 2:50 PM
Happy national foreskin day!
April 04 2024 1:45 PM
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
Scarlet fever: exploring our fascination with blood
March 13 2024 1:47 PM
On Anal Sex Day, crack up with The Bottom's Digest
April 18 2024 10:22 AM
Plus: Featured Video
Latest Stories
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
Yes, HIV-positive people can safely breastfeed
June 26 2024 12:59 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
Court rules to keep PrEP coverage under Obamacare
June 21 2024 5:42 PM
In honor of Juneteenth 2024, meet The Normal Anomaly
June 19 2024 1:39 PM
What is Juneteenth?
June 19 2024 11:30 AM
As Pride party season begins, the CDC urges mpox vaccinations
May 16 2024 6:52 PM
Advocacy in action with AIDSWatch
May 09 2024 12:30 PM
The Talk: Thriving with HIV
May 08 2024 10:45 AM
The Talk: What HIV isn’t
May 07 2024 10:48 AM
The Talk: Finding balance with HIV
May 06 2024 10:51 AM
Justice Dept plans to reschedule marijuana as a lower-risk drug
May 03 2024 2:40 PM
The Talk: Starting your journey with HIV
May 03 2024 2:00 PM
Why is a mother’s mental health so important? A doctor explains
May 01 2024 1:38 PM
Walmart to close all of its health care clinics
April 30 2024 12:30 PM
Vampire facial spa infected several women with HIV
April 29 2024 7:26 PM